武汉凯德基诺生物技术

Wuhan KDGene Biotech is a specialized biotechnology company focused on the development and manufacturing of adeno-associated virus (AAV) gene therapy products. Founded by industry pioneer Dr. Wu Xiaobing, the company operates a leading AAV CDMO platform that provides end-to-end services from vector design and optimization to large-scale GMP manufacturing. KDGene's proprietary technology focuses on enhancing vector yield, purity, and tissue specificity to improve the safety and efficacy of gene therapies. In addition to its CDMO business, the company is advancing an internal pipeline of gene therapy candidates targeting ophthalmic and rare genetic diseases. KDGene is headquartered in Wuhan's Optics Valley and plays a critical role in the Chinese gene therapy ecosystem.